pharmaphorum Podcast

AI, start-ups, and the future of human health: AION Labs’ Mati Gill

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest. AION Labs is a venture studio built by a coalition of ph

ESMO26: Taiho Oncology on improving the lives of patients with cancer, their families, and their caregivers

At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metasta

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a co

Menopause is an urgent global health issue: Bayer’s Cecilia Caetano

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* By 2030, 1.2 billion women worldwide will be menopausal or post-menopausal

AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie

Even the most promising innovation still depends on strong governance, resilient operations, and confidence in sensitive data. In a new pharmaphorum podcast, web editor

AI and pharma launch - Within3's Jason Smith

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new pharmaphorum podcast, host Nicole Raleigh s

Bioconvergence & future human health, with Shai Melcer

Bioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medici

AI-enabled pharmacovigilance, with Updesh Dosanjh

Artificial intelligence is dramatically transforming the landscape for every part of pharma. One area where AI is both essential to implement and important to get right i

Getting predictive technologies to patients, with Concr

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators th

Europe for life sciences and for patients, with BeOne Medicines

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Europe continues to offer major life sciences advantages: deep scientific t

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* When it comes to digital innovation and AI, consideration of using and impl

Delivering prevention at scale, PA Consulting’s James Davis

Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at

Understanding Operation Trialblazer, with Dr Harpreet Singh

For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lig

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients a

Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the age

CAMP4 on a new class of ASO in gene under expression

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe

Purespring on nephrology & gene therapy in kidney disease

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphor

Parexel: Flawless execution, policy shifts & patient-centric design

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast,

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immun